Temporary Topic | Original Article

ABSTRACT:

A number of infectious disease treatments are available today. However, infectious diseases still pose serious threats to patients because of the development of antibiotic resistance and the emergence of new infectious diseases. As on date, about 400 drugs including New Chemical Entities (NCEs), biologics, vaccines, new dosage forms and drug combinations are at different phases of their development against infectious diseases. Several antibiotics have been discovered following the discovery of penicillin. These antibiotics had been helpful in treatment of infectious diseases considered dread for centuries. The advent of multiple drug resistance in microbes has posed new challenge to researchers. The scientists are now evaluating alternatives for combating infectious diseases. This article provides preliminary information about New Chemical Entities (NCEs) for which New Drug Application (NDA) has been submitted by pharmaceutical companies to Food and Drug Administration (FDA) or which are in Phase III of their clinical trial. It would be interesting to see how many of New Chemical Entities (NCEs), among those discussed in this article, will see the face of the future.